Parameters | N = 188 |
---|---|
Operative time, median (IQR), minutes | 185 (130–260) |
Blood loss, median (IQR), ml | 200 (150–450) |
Blood transfusion | 1 (0.5%) |
PLND | Â |
 Extended PLND | 170 (90.4%) |
 Limited PLND | 18 (9.6%) |
 Nodal involvement | 12 (6.4%) |
Complications | Â |
 Clavien grade I, II | 22 (11.7%) |
 Clavien grade ≥ III | 5 (2.7%) |
Pathologic stage | Â |
 High-risk localized (≤ pT2c) | 63 (33.5%) |
 High-risk locally advanced | 125 (66.5%) |
  pT3a | 75 (39.9%) |
  ≥ pT3b | 50 (26.6%) |
Pathologic Gleason score | Â |
 7 | 81 (43.1%) |
 8 | 74 (39.4%) |
  ≥ 9 | 33 (17.6%) |
PSMs | Â |
 Overall | 50 (26.6%) |
 In pT2 cancer | 16 (8.5%) |
 In pT3 cancer | 34 (18.1%) |
Adjuvant treatment | Â |
 Overall | 63 (33.5%) |
 Radiotherapy | 25 (13.3%) |
 Hormonal therapy | 38 (20.2%) |
Salvage treatment | Â |
 Overall | 35 (18.6%) |
 Radiotherapy | 10 (5.3%) |
 Hormonal therapy | 15 (8.0%) |
 Secondary after adjuvant therapy | 10 (5.3%) |
Follow-up duration, median (IQR), month | 66.5 (13–94) |
 BCR | 42 (22.3%) |
 Time to BCR, median (IQR) | 10.5 (3.5–26) |